2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
0
Active Trials
4
Rare Diseases
across 7 areas
0
News (30d)
Quiet
Reviva Pharmaceuticals, Inc. is a company with 2 orphan drug designations across 4 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| heritable pulmonary arterial hypertension | 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one hydrochloride | Des.TrialAppr. |
| idiopathic pulmonary arterial hypertension | 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one hydrochloride | Des.TrialAppr. |
| idiopathic pulmonary fibrosis | 6-(4-(4-(2,3-Dicholorophenyl) piperazin-1-yl) butoxy)-2H-benzo [b] [1,4] oxazin-3(4H)-one hydrochloride | Des.TrialAppr. |
| pulmonary arterial hypertension | 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one hydrochloride | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
16
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
16
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio